25 June 2015 - Deborah Wilkes
Archived
Abbott has confirmed its support for Mylan's standalone strategy, and plans to use its 14.5% stake in Mylan to back the generics company's hostile takeover bid for Perrigo. Meanwhile, Teva continues to pursue its hostile takeover of Mylan, and has increased its stake in the company to 4.61%.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.